首页> 美国卫生研究院文献>Clinical Medicine Insights. Oncology >Complete Radiological Response of Recurrent Metastatic Adrenocortical Carcinoma to Pembrolizumab and Mitotane
【2h】

Complete Radiological Response of Recurrent Metastatic Adrenocortical Carcinoma to Pembrolizumab and Mitotane

机译:复发转移性肾上腺皮质癌的完整放射响应彭洛洛洛柳豆和巨烟性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Adrenocortical carcinoma (ACC) is a rare malignancy with a poor prognosis. Treatment options for ACC are limited, with resection the main intervention. Most cases present in late metastatic cases, and data regarding effective therapies is limited. We report a case of ACC in a 40-year-old woman with history of ACC postadrenalectomy, who presented with recurrent metastatic ACC in the left perinephric space. She was started on pembrolizumab which was added to her mitotane maintenance therapy. Complete radiological response was achieved after 4 cycles of pembrolizumab. As far as we know, this is the first case to achieve complete radiological response with mitotane and pembrolizumab in recurrent metastatic ACC, with negative prognostic markers and no prior radiotherapy. As our findings are in the setting of one clinical case, we suggest the need to perform a trial to assess the benefit of combining mitotane and pembrolizumab in treating metastatic ACC.
机译:肾上腺皮质癌(ACC)是一种罕见的恶性肿瘤,预后差。 ACC的治疗方案有限,分解主要干预。大多数病例存在于后期转移性病例中,有关有效疗法的数据有限。我们举报了一个40岁女性的ACC的ACC案件,其中患有左下透露空间的复发转移码头。她在彭布洛替妥替纳豆中开始,添加到她的培养疗法疗法中。在4个蛋白唾液中达到完全放射响应。据我们所知,这是第一种实现含有Mitotane和Pembrolizumab在复发转移癌中的完全放射响应的案例,具有阴性预后标志物和未预先放射治疗。随着我们的研究结果在设置一个临床案例中,我们建议需要进行试验,以评估Mitotane和Pembrolizumab在治疗转移ACC中的益处。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号